Investing.com - Baudax Bio reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Baudax Bio announced earnings per share of $-0.3928 on revenue of $238K. Analysts polled by Investing.com anticipated EPS of $-0.7200 on revenue of $1.41M.
Baudax Bio shares are down 48.09% from the beginning of the year , still down 99.08% from its 52 week high of $19.25 set on Tuesday, November 9, 2021.
Baudax Bio follows other major Healthcare sector earnings this month
Baudax Bio's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar